Oncology
Circulating tumor DNA dynamics and clinical outcome in metastatic colorectal cancer patients undergoing front-line chemotherapy | Ghidini M, et al. | Clin Cancer Res. | Dec. 2024
Michele Ghidini, Jens Claus Hahne, Chiara Senti, Timon Heide, Paula Z Proszek, Ridwan Shaikh, Paul Carter, Mike Hubank, et al. Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line Chemotherapy. Clinical Cancer Research; 2025: 31, (4) 707-718. Nonacus product: Custom panels Background Eight hundred sixty-two plasma samples were collected 4-weekly…
Read More726P Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma | Ronchi CL, et al. | Annals of Oncology | Oct. 2023
Ronchi CL, Lippert J, Smith G, Altieri B, Elhassan YS, Landwehr LS, et al. 726P Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma. Annals of Oncology. 2023;34:S500. Nonacus product: Custom panels Background Adrenocortical carcinoma (ACC) is a rare aggressive endocrine cancer with heterogeneous behaviour. Disease surveillance relies on…
Read MoreOR04-5 Circulating cell-free DNA-based biomarkers For prognostication and disease surveillance in adrenocortical carcinoma | Altieri B, et al | Journal of the Endocrine Society | Nov. 2022
Lippert J, Smith G, Appenzeller S, Landwehr LS, Prete A, Steinhauer S, et al. Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma. European Journal of Endocrinology. 2024;lvae022. Nonacus products: Sample collection and isolation / Custom panels Abstract Adrenocortical carcinoma (ACC) is a rare aggressive cancer with heterogeneous behaviour. Disease surveillance relies on…
Read MoreMutation detection in saliva from oral cancer patients | Ahmed AA, et al | Oral Oncology | Apr. 2024
Ahmed AA, Sborchia M, Bye H, Roman-Escorza M, Amar A, Henley-Smith R, et al. Mutation detection in saliva from oral cancer patients. Oral Oncology. 2024;151:106717. Nonacus product: Custom panels Abstract The incidence of head and neck squamous cell carcinoma (HNSCC) continues to increase and although advances have been made in treatment, it still has a…
Read MoreCirculating tumour DNA detection by the urine-informed analysis of archival serum samples from muscle-invasive bladder cancer patients | BinHumaid FS, et al | European Urology | Jan. 2024
BinHumaid FS, Goel A, Gordon NS, Abbotts B, Cheng KK, Zeegers MP, et al. Circulating Tumour DNA Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients. European Urology. 2024;S0302-2838. Nonacus product: Oncology Abstract No abstract available
Read MoreMinimal residual disease monitoring in radically treated non-small cell lung cancer: challenges and future directions | O’Sullivan HM, et al | OncoTargets and Therapy | Dec. 2023
O’Sullivan HM, Feber A, Popat S. Minimal residual disease monitoring in radically treated non-small cell lung cancer: challenges and future directions. OncoTargets and Therapy. 2023;249-59. Nonacus product: Oncology Abstract Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it is clinically or radiologically evident. Minimal residual disease (MRD) is an advancing area…
Read MoreBaseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients | Pascual J, et al | Clinical Cancer Research | Oct. 2023
Pascual J, Gil-Gil M, Proszek P, Zielinski C, Reay A, Ruiz-Borrego M, et al. Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients. Clinical Cancer Research. 2023;29(20):4166-77. Nonacus product: Oncology Abstract Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA)…
Read MorePB2000: A comprehensive NGS panel approach for clinical genomic analysis in haematological malignancy | Mason J, et al | HemaSphere | Aug. 2023
Mason J, Skowronska A, Barrows N, Hill D, Page P, Hamblin A, Clokie S, Feber A, Hastings R, Cross N. PB2000: A comprehensive NGS panel approach for clinical genomic analysis in haematological malignancy. HemaSphere. 2023;7(S3):e76738e4. Nonacus product: Oncology Abstract Delivery of comprehensive genomic analysis in hematological malignancies (HM) has until recently relied on multiple techniques…
Read MorePerformance of DNA-based biomarkers for classification of adrenocortical carcinoma: A prognostic study | Lippert J, et al | European Journal of Endocrinology | Aug. 2023
Lippert J, Dischinger U, Appenzeller S, Prete A, Kircher S, Skordilis K, et al. Performance of DNA-based biomarkers for classification of adrenocortical carcinoma: A prognostic study. European Journal of Endocrinology. 2023;189(2):262-70. Nonacus product: Germline Abstract Adrenocortical carcinoma (ACC) is a rare aggressive malignancy with heterogeneous clinical outcomes. Recent studies proposed a combination of clinical/histopathological parameters…
Read MoreP-113 Evidence for early detection of metastatic variants and tumour evolution in ctDNA of patients with oesophageal adenocarcinoma | Openshaw M, et al | Annals of Oncology | Jun. 2023
Openshaw M, Hastings R, Jamal-Hanjani M, Swanton C, Shaw J, et al. P-113 Evidence for early detection of metastatic variants and tumour evolution in ctDNA of patients with oesophageal adenocarcinoma. Annals of Oncology. 2023;34:S54. Nonacus product: Oncology Abstract Oesophageal adenocarcinoma (OA) has a dismal survival rate and no routine blood-borne biomarker. Circulating tumour DNA (ctDNA)…
Read More